IMPROVED SURVIVAL FOR PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA

Purpose: Despite improvement in chemotherapy and supportive care over the past two decodes, overall survival for patients with acute myelogenous leukemia (AML) remains poor; only 25% to 30% of individuals with this disorder will be cured. In 1987, we initiated a prospective multiinstitution study designed to improve longterm survival in adults with AML. Methods: We modified the usual 7-day treatment scheme of dounorubicim and cytarabine with high-dose cytarabine (HIDAC) on days 8 through 10(3+7+3). Allogeneic or autologous bone marrow transplantation (BMT) was offered to all patients who entered complete remission (CR) to decrease the rate of leukemic relapse. Data were analyzed by intention to treat. Results: CRs were achieved in 84 of 94 patients (89%; 95% confidence interval [CI], 83 to 95). Because of the high remission rate, factors previously thought to predict outcome, such as cytogenetics, WBC count, French-American-British (FAB) classification, sex, and age, were not useful prognostic variables. The overall survival rate for the entire cohort of patients from date of diagnosis is 55% at 5 years. Sixty percent of all patients who achieved a CR underwent marrow grafting. There was no significant difference in event free survival (EFS) at 5 years comparing patients assigned to receive allogeneic BMT with patients assigned to receive autologous BMT (56% v 45%, P = .54). (C) 1995 by American Society of Clinical Oncology. Conclusion: The long-term disease-free survival observed study is excellent compared with historical data. This improvement in survival is probably due to the high rate of remission induction, as well as to the effective nature of the consolidation therapy.